Abeona Therapeutics
NASDAQ: ABEOCleveland, US · Founded 2013 · 3 known investors
Find your way into Abeona Therapeutics
127 people in our graph share verified history with the Abeona Therapeutics team — schools, employers, funds. One of them is your warm intro.
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Founders & leadership
Abeona Therapeutics was founded in 2013 by Timothy Miller.
Board
Investors · 3
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$3.6M disclosed across 1 of 4 rounds · 1900–2023
▶$3.6MraisedNov 2014 · 9 investors · PharmaceuticalsRule 506(b)
- Al HawkinsExecutive Officer, Director
- Timothy MillerExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $3.6M
- Minimum investment
- $25K
- First sale
- Oct 2014
- Incorporated
- Limited Liability Company, Ohio, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Abeona Therapeutics went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Abeona Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences | The Manila Timesmanilatimes.net · Sep 2026
Abeona Therapeutics (ABEO) lifts ZEVASKYN revenue 31% in Q2 2026 as cash hits $146.8Mstocktitan.net · Aug 2026Frequently asked questions
- What does Abeona Therapeutics do?
- Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
- Who founded Abeona Therapeutics?
- Abeona Therapeutics was founded by Timothy Miller in 2013.
- Who are Abeona Therapeutics's investors?
- Abeona Therapeutics's investors include Elysia Capital.
- How much funding has Abeona Therapeutics raised?
- Abeona Therapeutics has disclosed $3.6M raised across 1 of its 4 known rounds.
- Where is Abeona Therapeutics headquartered?
- Abeona Therapeutics is headquartered in Cleveland, US.